For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved ...

A flawed new algorithm for distributing lungs to transplant patients wound up putting people with Type O blood at a ...

A tracer known as FAPI performed better than the commonly used 18F-FDG for capturing early signs of pulmonary fibrosis on PET ...

What is the life expectancy of someone with interstitial lung disease? Answered by Dr. Howard E. Lewine M.D. Chief Medical ...

Amivantamab plus lazertinib improved PFS over osimertinib as first-line treatment for patients with EGFR-mutant, advanced NSCLC.

In 5-year follow-up data from the phase III CROWN trial of ALK -positive advanced non-small cell lung cancer (NSCLC), ...

AstraZeneca's (AZN) cancer therapy Tagrisso approved in China as a first-line treatment of lung cancer patients in ...

Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the ...

ALSO READ: Lung Cancer Awareness Month 2022 ... compared to 3D-CRT (26.6 per cent), as well as progression-free survival ...

AstraZeneca has received Japanese approval for Tagrisso plus chemotherapy as first-line treatment for non-small cell lung ...

AI’s ability to outperform human lung cancer detection is rapidly evolving, as was highlighted in the clinical science ...